Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech firesales -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (3575)	9/6/2018 8:09:25 AM
From: Biotech Jim	Respond to of 3661

sciencedirect.com Our data indicate that the transfected as well as the infected cells produce a large amount of the IDS enzyme, which is efficiently endocytosed into neuronal and glial cells through the mannose 6-phosphate (M6P) receptor system. jbc.org Most lysosomal enzymes carry mannose 6-phosphate (M6P) residues, a specific marker that enables their binding to cellular mannose 6- phosphate receptors (MPRs) (5). Binding to MPRs localized to the trans Golgi network separates newly synthesized lysosomal enzymes from the secretory route and targets them to the endosomal/lysosomal compartment. Importantly, one of the two known MPRs, the insulin-like growth factor II/mannose 6-phosphate receptor, MPR300, also cycles to the plasma membrane where it efficiently internalizes exogenous lysosomal enzymes with M6P residues. The endocytic pathway provides the rationale for ERT as the lysosomally delivered enzyme can substitute for its defective counterpart and degrade the accumulated substrate(s).